Literature DB >> 4113870

Myeloma proteins as tumor-specific transplantation antigens.

R G Lynch, R J Graff, S Sirisinha, E S Simms, H N Eisen.   

Abstract

BALB/c mice immunized with myeloma proteins 315 or 460 made antibodies to the individually specific ("idiotypic") determinants of these proteins and suppressed growth of the corresponding transplanted tumor cells (MOPC-315 or MOPC-460). Stable, variant MOPC-315 tumors that produce only the light chain of protein 315 grew in several of the mice immunized with this protein, probably because the anti-idiotypic immune response selects against those myeloma cells that form the intact myeloma protein.

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4113870      PMCID： PMC426744          DOI： 10.1073/pnas.69.6.1540

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  15 in total

1.  Affinity labeling of a mouse myeloma protein which binds nitrophenyl ligands. Kinetics of labeling and isolation of a labeled peptide.

Authors:  E J Goetzl; H Metzger
Journal:  Biochemistry       Date:  1970-03-03       Impact factor: 3.162

2.  Mouse myeloma proteins with antihapten antibody acitivity. The protein produced by plasma cell tumor MOPC-315.

Authors:  H N Eisen; E S Simms; M Potter
Journal:  Biochemistry       Date:  1968-11       Impact factor: 3.162

Review 3.  Genetics of immunoglobulins in the mouse.

Authors:  M Potter; R Lieberman
Journal:  Adv Immunol       Date:  1967       Impact factor: 3.543

4.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

5.  Myeloma proteins with anti-hapten antibody activity: epsilon-2,4-dinitrophenyl lysine binding by the protein produced by mouse plasmacytoma MOPC-460.

Authors:  B M Jaffe; H N Eisen; E S Simms; M Potter
Journal:  J Immunol       Date:  1969-10       Impact factor: 5.422

6.  Experimental approaches to homogenous antibody populations. Myeloma proteins with antihapten antibody activity.

Authors:  H N Eisen; M C Michaelides; B J Underdown; E P Schulenburg; E S Simms
Journal:  Fed Proc       Date:  1970 Jan-Feb

7.  Studies of 125I trace labeling of immunoglobulin G by chloramine-T.

Authors:  S Sonoda; M Schlamowitz
Journal:  Immunochemistry       Date:  1970-11

8.  Rate of somatic mutation in immunoglobulin production by mouse myeloma cells.

Authors:  P Coffino; M D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  1971-01       Impact factor: 11.205

9.  Specificity and structure of the myeloma protein produced by mouse plasmacytoma MOPC-460.

Authors:  B M Jaffe; E S Simms; H N Eisen
Journal:  Biochemistry       Date:  1971-04-27       Impact factor: 3.162

10.  Quantitative investigations of idiotypic antibodies. IV. Inhibition by specific haptens of the reaction of anti-hapten antibody with its anti-idiotypic antibody.

Authors:  B W Brient; A Nisonoff
Journal:  J Exp Med       Date:  1970-11       Impact factor: 14.307
View more
  65 in total

1.  Genes predisposing to autoimmunity augment constitutive major histocompatibility complex class II-associated presentation of the self-antigen IgG2a in vivo.

Authors:  K Bartnes; X Li; M Iwamoto; S Izui; K Hannestad
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

2.  Deregulated cytokine network and defective Th1 immune response in multiple myeloma.

Authors:  M A Frassanito; A Cusmai; F Dammacco
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

3.  Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Authors:  Stephen J Schuster; Sattva S Neelapu; Barry L Gause; John E Janik; Franco M Muggia; Jon P Gockerman; Jane N Winter; Christopher R Flowers; Daniel A Nikcevich; Eduardo M Sotomayor; Dean S McGaughey; Elaine S Jaffe; Elise A Chong; Craig W Reynolds; Donald A Berry; Carlos F Santos; Mihaela A Popa; Amy M McCord; Larry W Kwak
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

4.  GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model.

Authors:  H R Galea; M Cogné
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 5.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

6.  The structure of two IgMs showing different activity from a patient with Waldenstrom's macroglobulinaemia.

Authors:  E Méndez; C Osuna; A Sánchez; Y Revilla; F Soriano; C Montalbán; J Seguí; J Avila
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 7.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

8.  Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.

Authors:  Z Dembic; K Schenck; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 9.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

10.  Development of orally active inhibitors of protein and cellular fucosylation.

Authors:  Nicole M Okeley; Stephen C Alley; Martha E Anderson; Tamar E Boursalian; Patrick J Burke; Kim M Emmerton; Scott C Jeffrey; Kerry Klussman; Che-Leung Law; Django Sussman; Brian E Toki; Lori Westendorf; Weiping Zeng; Xinqun Zhang; Dennis R Benjamin; Peter D Senter
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.